Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Sr. VP of IP, CSO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,795 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Exercise / conversion · Acquired 2,500 · Balance 19,795 F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 18,637 |
Reported balance
After 2026-08-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-12 · Tax withholding · Disposed 1,158 · Balance 18,637 F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 2,500 · Balance 0 F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2018 Filed Jun 29, 2018 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 295 | $9.13 | $2,693.35 |
DisclosureSEC source: 0001104659-18-043279 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:30 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,205 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-18-041853 · a4.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,295 Underlying: Common Stock · 7,205 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on March 3, 2016, which was the first anniversary of the date on which the option was granted. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:30 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 7,205 | $60.00 | $432,323.06 |
DisclosureSEC source: 0001104659-18-041853 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.9000 to $60.3500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:30 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 7,205 | $9.13 | $65,781.65 |
DisclosureSEC source: 0001104659-18-041853 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-18-033849 · a4.xml · derivative · entry 6 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on March 3, 2016, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 368 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-033849 · a4.xml · derivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 368 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 7,500 | $57.93 | $434,442.00 |
DisclosureSEC source: 0001104659-18-033849 · a4.xml · nonDerivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.9000 to $57.9500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 7,500 | $9.13 | $68,475.00 |
DisclosureSEC source: 0001104659-18-033849 · a4.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 368 | $57.93 | $21,316.62 |
DisclosureSEC source: 0001104659-18-033849 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.9000 to $57.9500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 368 | $9.24 | $3,400.32 |
DisclosureSEC source: 0001104659-18-033849 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,882 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · derivative · entry 12 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,868 Underlying: Common Stock · 10,882 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F6 · derivative.exercise_date: The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · derivative · entry 11 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 11,250 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F6 · derivative.exercise_date: The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · derivative · entry 10 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 10,882 | $57.90 | $630,067.80 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · nonDerivative · entry 8 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 10,882 | $9.24 | $100,549.68 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · nonDerivative · entry 7 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 16,250 | $55.23 | $897,542.75 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · nonDerivative · entry 6 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.8500 to $55.5000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 11,250 | $9.24 | $103,950.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · nonDerivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 20,000 | $52.03 | $1,040,558.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · nonDerivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.8500 to $52.2750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| May 11, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $7.90 | $158,000.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · derivative · entry 9 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 20,000 | $49.88 | $997,544.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.8500 to $49.9500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $7.90 | $158,000.00 |
DisclosureSEC source: 0001104659-18-032900 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001104659-18-010415 · a4.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 14, 2019. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 01:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-003366 · a4.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 20,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 01:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 20,000 | $48.04 | $960,716.00 |
DisclosureSEC source: 0001104659-18-003366 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.900 to $48.325, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 01:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $7.90 | $158,000.00 |
DisclosureSEC source: 0001104659-18-003366 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:38 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-002700 · a4.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 20,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:38 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 20,000 | $44.98 | $899,500.00 |
DisclosureSEC source: 0001104659-18-002700 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.95 to $45.00, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:38 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $7.90 | $158,000.00 |
DisclosureSEC source: 0001104659-18-002700 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 23:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $49.86 | $249,302.50 |
DisclosureSEC source: 0001104659-17-056609 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.8500 to $49.9000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 00:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,709 | $45.23 | $167,754.73 |
DisclosureSEC source: 0001104659-17-052304 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr.VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.0750 to $45.4750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 12, 2017 Filed Jul 14, 2017 20:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,735 | $44.90 | $167,701.50 |
DisclosureSEC source: 0001104659-17-045053 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,209 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 20:26 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 2,556 | $44.90 | $114,774.37 |
DisclosureSEC source: 0001104659-17-041823 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,944 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.900 to $44.925, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 22:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 10,000 | $39.86 | $398,558.00 |
DisclosureSEC source: 0001104659-17-037540 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.8500 to $39.9300, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 26, 2017 Filed May 31, 2017 00:58 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 2,500 | $35.90 | $89,757.50 |
DisclosureSEC source: 0001104659-17-036322 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9000 to $35.9250, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 25, 2017 Filed May 25, 2017 23:08 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,887 | $34.90 | $135,656.30 |
DisclosureSEC source: 0001104659-17-035312 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 23:08 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 1,613 | $34.90 | $56,293.70 |
DisclosureSEC source: 0001104659-17-035312 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,887 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. Read SEC document |
| April 24, 2017 Filed Apr 24, 2017 20:47 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 11,806 | $32.59 | $384,762.26 |
DisclosureSEC source: 0001104659-17-025476 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.3250 to $32.6750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012178 · a4.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-02-24 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 24, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.